相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Recent advances in clinical trials targeting the kynurenine pathway
Ananda Staats Pires et al.
PHARMACOLOGY & THERAPEUTICS (2022)
The Kynurenine Pathway and Cancer: Why Keep It Simple When You Can Make It Complicated
Roumaissa Gouasmi et al.
CANCERS (2022)
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy
Yu Fujiwara et al.
CANCER TREATMENT REVIEWS (2022)
Targeting metastatic cancer
Karuna Ganesh et al.
NATURE MEDICINE (2021)
Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer A Randomized Clinical Trial
Veronica Mariotti et al.
JAMA ONCOLOGY (2021)
TDO2 Promotes the EMT of Hepatocellular Carcinoma Through Kyn-AhR Pathway
Lei Li et al.
FRONTIERS IN ONCOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Quinolinate Phosphoribosyltransferase Promotes Invasiveness of Breast Cancer Through Myosin Light Chain Phosphorylation
Chien-Liang Liu et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
Remy Thomas et al.
FRONTIERS IN ONCOLOGY (2021)
The Differential Selectivity of Aryl Hydrocarbon Receptor (AHR) Agonists towards AHR-Dependent Suppression of Mammosphere Formation and Gene Transcription in Human Breast Cancer Cells
Nao Saito et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2021)
A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer
Nuria Kotecki et al.
JOURNAL OF IMMUNOTHERAPY (2021)
Integrated Molecular Characterization to Reveal the Association between Kynurenine 3-Monooxygenase Expression and Tumorigenesis in Human Breast Cancers
Yuk-Wah Tsang et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
Detrimental activation of AhR pathway in cancer: an overview of therapeutic strategies
Delphine Leclerc et al.
CURRENT OPINION IN IMMUNOLOGY (2021)
Anxiety and depression after breast cancer: The predictive role of monoamine levels
Joana Perez-Tejada et al.
EUROPEAN JOURNAL OF ONCOLOGY NURSING (2021)
TDO2 knockdown inhibits colorectal cancer progression via TDO2-KYNU-AhR pathway
Long Zhao et al.
GENE (2021)
3-hydroxy-L-kynurenamine is an immunomodulatory biogenic amine
Cristina C. Clement et al.
NATURE COMMUNICATIONS (2021)
Monitoring the kynurenine system: Concentrations, ratios or what else?
Masaru Tanaka et al.
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE (2021)
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma
Yousef Zakharia et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
GCH1 induces immunosuppression through metabolic reprogramming and IDO1 upregulation in triple-negative breast cancer
Jin-Li Wei et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Surface Expression of Kynurenine 3-Monooxygenase Promotes Proliferation and Metastasis in Triple-Negative Breast Cancers
Min-Hua Lai et al.
CANCER CONTROL (2021)
Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists
Karen S. Johnson et al.
JOURNAL OF BREAST IMAGING (2021)
Reliable chromatographic assay for measuring of indoleamine 2,3-dioxygenase 1 (IDO1) activity in human cancer cells
Ilona Sadok et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2021)
Simultaneous voltammetric analysis of tryptophan and kynurenine in culture medium from human cancer cells
Ilona Sadok et al.
TALANTA (2020)
Chemoresistance was correlated with elevated expression and activity of indoleamine 2,3-dioxygenase in breast cancer
Yang Zhao et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)
Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain
Dayana Herrera-Rios et al.
FRONTIERS IN IMMUNOLOGY (2020)
Kynurenine 3-monooxygenase upregulates pluripotent genes through beta-catenin and promotes triple-negative breast cancer progression
Tzu-Ting Huang et al.
EBIOMEDICINE (2020)
Codelivered Chemotherapeutic Doxorubicin via a Dual-Functional Immunostimulatory Polymeric Prodrug for Breast Cancer Immunochemotherapy
Yang Lan et al.
ACS APPLIED MATERIALS & INTERFACES (2020)
Gene expression of indoleamine and tryptophan dioxygenases and three long non-coding RNAs in breast cancer
Soudeh Ghafouri-Fard et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2020)
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
Yuanyuan Zhang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Comprehensive Analysis of the Expression and Prognosis for TDO2 in Breast Cancer
Qiang Liu et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression
Ahmed Sadik et al.
CELL (2020)
Indoximod opposes the immunosuppressive effects mediated by IDO and TDO via modulation of AhR function and activation of mTORC1
Erik L. Brincks et al.
Oncotarget (2020)
Salinomycin promotes T-cell proliferation by inhibiting the expression and enzymatic activity of immunosuppressive indoleamine-2,3-dioxygenase in human breast cancer cells
Azubuike Peter Ebokaiwe et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2020)
Searching for Peripheral Biomarkers in Neurodegenerative Diseases: The Tryptophan-Kynurenine Metabolic Pathway
Nora Torok et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Differential kynurenine pathway metabolism in highly metastatic aggressive breast cancer subtypes: beyond IDO1-induced immunosuppression
Benjamin Heng et al.
BREAST CANCER RESEARCH (2020)
A tumor acidity activatable and Ca2+-assisted immuno-nanoagent enhances breast cancer therapy and suppresses cancer recurrence
Yanhua Li et al.
CHEMICAL SCIENCE (2020)
A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma
Lisa Greene et al.
MOLECULAR CANCER RESEARCH (2019)
Reversal of Triple-Negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of Immunosuppression
Thomas J. Rogers et al.
MOLECULAR CANCER RESEARCH (2019)
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Kyung Hae Jung et al.
CLINICAL CANCER RESEARCH (2019)
Tryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy
Concetta Elisa Onesti et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina Long et al.
LANCET ONCOLOGY (2019)
Breast cancer
Nadia Harbeck et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Resistance Exercise Reduces Kynurenine Pathway Metabolites in Breast Cancer Patients Undergoing Radiotherapy
Philipp Zimmer et al.
FRONTIERS IN ONCOLOGY (2019)
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer A Phase 1 Study
Leisha A. Emens et al.
JAMA ONCOLOGY (2019)
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
Molecular logic of mTORC1 signalling as a metabolic rheostat
Alexander J. Valvezan et al.
NATURE METABOLISM (2019)
Inhibition of Indoleamine 2,3-Dioxygenase Enhances the Therapeutic Efficacy of Immunogenic Chemotherapeutics in Breast Cancer
Jian Gao et al.
JOURNAL OF BREAST CANCER (2019)
IDO1 in cancer: a Gemini of immune checkpoints
Lijie Zhai et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2018)
A patent review of IDO1 inhibitors for cancer
Jae Eun Cheong et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2018)
Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme
Todd A. Triplett et al.
NATURE BIOTECHNOLOGY (2018)
High AHR expression in breast tumors correlates with expression of genes from several signaling pathways namely inflammation and endogenous tryptophan metabolism
Sophie Vacher et al.
PLOS ONE (2018)
A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer
Hatem Soliman et al.
Oncotarget (2018)
High Indoleamine 2,3-Dioxygenase Is Correlated With Microvessel Density and Worse Prognosis in Breast Cancer
Lijuan Wei et al.
FRONTIERS IN IMMUNOLOGY (2018)
The Aryl Hydrocarbon Receptor and Tumor immunity
Ping Xue et al.
FRONTIERS IN IMMUNOLOGY (2018)
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
Asha Nayak-Kapoor et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
Tara C. Mitchell et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Metabolite and lipoprotein responses and prediction of weight gain during breast cancer treatment
Torfinn S. Madssen et al.
BRITISH JOURNAL OF CANCER (2018)
Pilot Study of Metabolomics and Psychoneurological Symptoms in Women With Early Stage Breast Cancer
Debra E. Lyon et al.
BIOLOGICAL RESEARCH FOR NURSING (2018)
Improved Radiosynthesis and Biological Evaluations of L- and D-1-[18F]Fluoroethyl-Tryptophan for PET Imaging of IDO-Mediated Kynurenine Pathway of Tryptophan Metabolism
Yangchun Xin et al.
MOLECULAR IMAGING AND BIOLOGY (2017)
Tryptophan metabolite activation of the aryl hydrocarbon receptor regulates IL-10 receptor expression on intestinal epithelia
J. M. Lanis et al.
MUCOSAL IMMUNOLOGY (2017)
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors activate the aryl hydrocarbon receptor
Benjamin J. Moyer et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2017)
Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer
Dyah L. Dewi et al.
ONCOIMMUNOLOGY (2017)
Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer
Daniel E. Carvajal-Hausdorf et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Safety of epacadostat 100 mg bid plus pembrolizumab 200 mg Q3W in advanced solid tumors: Phase 2 data from ECHO-202/KEYNOTE-037.
Omid Hamid et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Breast Cancer: Multiple Subtypes within a Tumor?
Syn Kok Yeo et al.
TRENDS IN CANCER (2017)
Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects
Abdulla A-B Badawy
INTERNATIONAL JOURNAL OF TRYPTOPHAN RESEARCH (2017)
Expression Pattern and Clinicopathological Relevance of the Indoleamine 2,3-Dioxygenase 1/Tryptophan 2,3-Dioxygenase Protein in Colorectal Cancer
I-Chien Chen et al.
DISEASE MARKERS (2016)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
David H. Munn et al.
TRENDS IN IMMUNOLOGY (2016)
Lung cancer-derived galectin-1 contributes to cancer associated fibroblast-mediated cancer progression and immune suppression through TDO2/kynurenine axis
Ya-Ling Hsu et al.
ONCOTARGET (2016)
The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells
Caroline Jochems et al.
ONCOTARGET (2016)
An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER-/PR-/Her2- Human Breast Cancer Cells
Olga Novikov et al.
MOLECULAR PHARMACOLOGY (2016)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The aryl hydrocarbon receptor (AhR) mediates resistance to apoptosis induced in breast cancer cells
Kanae Bekki et al.
PESTICIDE BIOCHEMISTRY AND PHYSIOLOGY (2015)
Levels in neurotransmitter precursor amino acids correlate with mental health in patients with breast cancer
K. Huefner et al.
PSYCHONEUROENDOCRINOLOGY (2015)
Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models
Jessica Spahn et al.
Journal for ImmunoTherapy of Cancer (2015)
Expression of the Kynurenine Pathway in Human Peripheral Blood Mononuclear Cells: Implications for Inflammatory and Neurodegenerative Disease
Simon P. Jones et al.
PLOS ONE (2015)
Accumulation of an Endogenous Tryptophan-Derived Metabolite in Colorectal and Breast Cancers
Paolo Puccetti et al.
PLOS ONE (2015)
Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
Ivan Theate et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Treatment of HER2-positive breast cancer
Maria Cristina Figueroa-Magalhaes et al.
BREAST (2014)
Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy.
Mario R. Mautino et al.
CANCER RESEARCH (2014)
Synergistic antitumor effects of combinatorial immune checkpoint inhibition with anti-PD-1/PD-L antibodies and the IDO pathway inhibitors NLG-919 and indoximod in the context of active immunotherapy
Mario R. Mautino et al.
CANCER RESEARCH (2014)
Aryl hydrocarbon receptor control of a disease tolerance defence pathway
Alban Bessede et al.
NATURE (2014)
Identification of Cinnabarinic Acid as a Novel Endogenous Aryl Hydrocarbon Receptor Ligand That Drives IL-22 Production
Margaret M. Lowe et al.
PLOS ONE (2014)
Involvement of the Kynurenine Pathway in Human Glioma Pathophysiology
Seray Adams et al.
PLOS ONE (2014)
IDO is highly expressed in breast cancer and breast cancer-derived circulating microvesicles and associated to aggressive types of tumors by in silico analysis
M. T. Isla Larrain et al.
TUMOR BIOLOGY (2014)
Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR
Ulrike M. Litzenburger et al.
ONCOTARGET (2014)
The treatment and survival of patients with triple negative breast cancer in a London population
Shrestha Pal et al.
SPRINGERPLUS (2014)
Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression
Jing-Yi Chen et al.
BREAST CANCER RESEARCH (2014)
A joint analysis of metabolomics and genetics of breast cancer
Xiaohu Tang et al.
BREAST CANCER RESEARCH (2014)
Biological subtypes of breast cancer: Prognostic and therapeutic implications
Ozlem Yersal et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2014)
Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease
Amos A. Fatokun et al.
AMINO ACIDS (2013)
C-reactive protein predicts fatigue independently of depression in breast cancer patients prior to chemotherapy
Maria M. Pertl et al.
BRAIN BEHAVIOR AND IMMUNITY (2013)
The Endogenous Tryptophan Metabolite and NAD+ Precursor Quinolinic Acid Confers Resistance of Gliomas to Oxidative Stress
Felix Sahm et al.
CANCER RESEARCH (2013)
Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion
Michael Platten et al.
CANCER RESEARCH (2012)
Studies on Tissue and Cellular Distribution of Indoleamine 2,3-Dioxygenase 2: The Absence of IDO1 Upregulates IDO2 Expression in the Epididymis
Masakazu Fukunaga et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2012)
Tryptophan metabolism in breast cancers: molecular imaging and immunohistochemistry studies
Csaba Juhasz et al.
NUCLEAR MEDICINE AND BIOLOGY (2012)
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
Luc Pilotte et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development
Courtney Smith et al.
CANCER DISCOVERY (2012)
IDO inhibits a tryptophan sufficiency signal that stimulates mTOR A novel IDO effector pathway targeted by D-1-methyl-tryptophan
Richard Metz et al.
ONCOIMMUNOLOGY (2012)
Cinnabarinic Acid, an Endogenous Metabolite of the Kynurenine Pathway, Activates Type 4 Metabotropic Glutamate Receptors
F. Fazio et al.
MOLECULAR PHARMACOLOGY (2012)
Structure, mechanism, and substrate specificity of kynureninase
Robert S. Phillips
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Deconstructing the molecular portraits of breast cancer
Aleix Prat et al.
MOLECULAR ONCOLOGY (2011)
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Christiane A. Opitz et al.
NATURE (2011)
3-Hydroxykynurenine Suppresses CD4+ T-Cell Proliferation, Induces T-Regulatory-Cell Development, and Prolongs Corneal Allograft Survival
Sarah S. Zaher et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2011)
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
Xiangdong Liu et al.
BLOOD (2010)
An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
Joshua D. Mezrich et al.
JOURNAL OF IMMUNOLOGY (2010)
Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors
Holly K. Koblish et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism
Nam Trung Nguyen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Tryptophan Catabolism by Indoleamine 2,3-Dioxygenase 1 Alters the Balance of TH17 to Regulatory T Cells in HIV Disease
David Favre et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Kynurenic Acid Is a Potent Endogenous Aryl Hydrocarbon Receptor Ligand that Synergistically Induces Interleukin-6 in the Presence of Inflammatory Signaling
Brett C. DiNatale et al.
TOXICOLOGICAL SCIENCES (2010)
On the Biological Importance of the 3-hydroxyanthranilic Acid: Anthranilic Acid Ratio
L. Gail Darlington et al.
INTERNATIONAL JOURNAL OF TRYPTOPHAN RESEARCH (2010)
Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer
Aaron S. Mansfield et al.
BMC CANCER (2009)
Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway
Helen J. Ball et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo
Laura Amori et al.
JOURNAL OF NEUROCHEMISTRY (2009)
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Maggie C. U. Cheang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
The aryl hydrocarbon receptor in immunity
Charlotte Esser et al.
TRENDS IN IMMUNOLOGY (2009)
Immune system modulation in patients with malignant and benign breast disorders: tryptophan degradation and serum neopterin
Gozde Girgin et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS (2009)
Immune escape as a fundamental trait of cancer: focus on IDO
G. C. Prendergast
ONCOGENE (2008)
3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis
Tolmoko Hayashi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice
Helen J. Ball et al.
GENE (2007)
Heme oxygenase-1 inhibits rat and human breast cancer cell proliferation: mutual cross inhibition with indoleamine 2,3-dioxygenase (vol 19, pg 1957, 2005)
Marcelo Hill et al.
FASEB JOURNAL (2006)
Heme oxygenase-1 inhibits rat and human breast cancer cell proliferation: mutual cross inhibition with indoleamine 2,3-dioxygenase
M Hill et al.
FASEB JOURNAL (2005)
Tryptophan catabolism: Identification and characterization of a new degradative pathway
KL Colabroy et al.
JOURNAL OF BACTERIOLOGY (2005)
A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation
D Braun et al.
BLOOD (2005)
GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase
DH Munn et al.
IMMUNITY (2005)
Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy
AJ Muller et al.
NATURE MEDICINE (2005)
The role of IFN-gamma and TNF-alpha-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase
CM Robinson et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2005)
Regulatory T cells mediate maternal tolerance to the fetus
VR Aluvihare et al.
NATURE IMMUNOLOGY (2004)
Indoleamine 2,3-dioxygenase activity and L-tryptophan transport in human breast cancer cells
MT Travers et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2004)
AβI-42 induces production of quinolinic acid by human macrophages and microglia
GJ Guillemin et al.
NEUROREPORT (2003)
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
C Sotiriou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Tryptophan and the immune response
JR Moffett et al.
IMMUNOLOGY AND CELL BIOLOGY (2003)
T cell apoptosis by tryptophan catabolism
I Fallarino et al.
CELL DEATH AND DIFFERENTIATION (2002)
Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase
G Frumento et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Heme: A regulator of rat hepatic tryptophan 2,3-dioxygenase?
SY Ren et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2000)
分享论文
